Before the opening bell of Tuesday’s regular trading, GT Biopharma Inc.’s (NASDAQ: GTBP) shares rose by a healthy 154% in pre-market. An increase in the share price came following positive results associated with one of its product candidates around prostate cancer.
So, what are the results?
GT Biopharma develops immuno-oncology therapy products utilizing its proprietaryTriKE NK cell engager technology.Its TriKE platform is designed to facilitate the process of activating and redirect the target cell killing abilities of patients’ own natural killer cells (NK cells) without requiring large quantities of donor or autologous NK cells or induced pluripotent stem cells (iPSC).
With the University of Minnesota as its exclusive worldwide licensee, company is developing and commercializing therapies using TriKE technology.A Phase 1/2 multicenter trial is being conducted to evaluate the effectiveness of GT Biopharma’s lead TriKE product candidate, GTB-3550 TriKE.Treatment of the leukemia and related diseases will be performed using the product.
A prospective therapy for the treatment of prostate cancer generated positive preclinical results for GT Biopharma’s ROR1 TriKE product candidate, as announced the company yesterday.
- Recently, research has shown that the ROR1 transmembrane protein appears to promote migration and invasion, and influences the prognosis of solid tumor cancer by influencing the metastatic capacity.
- It may be possible to eliminate cancer cells expressing ROR1, and restoring the function of NK cells, with TriKE, in order to limit the possibility of cancer cells spreading throughout the body and enlarging their invasiveness.
- A number of preclinical models of prostate cancer examined the ROR1 TriKE, and those models found the TriKE effective in promoting the NK cell killer’s capability to kill multiple prostate cancers.
- Significant TriKE stimulation also increased NK cell activation and IFN production from the NK cell.